Welcome to our dedicated page for Avid Bioservices news (Ticker: CDMOP), a resource for investors and traders seeking the latest updates and insights on Avid Bioservices stock.
Overview of Avid Bioservices
Avid Bioservices (CDMO) is a dedicated contract development and manufacturing organization specializing in the development and CGMP manufacturing of biologics. With over three decades of experience, the company offers a comprehensive suite of services that include process development, clinical and commercial drug substance manufacturing, and a broad range of testing and regulatory compliance services. Key industry terms such as CGMP manufacturing, process development, and biologics production are central to its operations, positioning Avid as an essential partner for biotechnology and pharmaceutical companies.
Core Business Areas
Avid Bioservices provides extensive services tailored to meet the evolving needs of life sciences companies. Its operations are divided into several critical segments:
- Process Development: Encompassing cell line development, upstream and downstream process optimization, analytical methods development, and comprehensive testing and characterization, this segment focuses on building a robust foundation for biologic production.
- CGMP Manufacturing: Operating state-of-the-art, fully compliant facilities, the company handles both clinical and commercial-scale production of drug substances. It covers bulk packaging, release and stability testing, and supports regulatory submissions.
- Comprehensive Support Services: In addition to production, Avid offers support in regulatory strategy, assay development, and data analysis, allowing clients to navigate the complex landscape of biologic development with confidence.
Market Position and Industry Significance
Avid Bioservices has established itself as a reliable partner in the highly specialized field of biologics development. Its longstanding track record of consistent regulatory compliance and commitment to quality has earned it trust among leading pharmaceutical and biotech innovators. The company’s ability to manage end-to-end services — from early-stage development to final commercialization — highlights its expertise and deep industry knowledge, making it a significant player in the global CDMO landscape.
Expertise and Operational Excellence
The company prioritizes technological innovation and process optimization to meet the rigorous demands of its clients. Its investments in state-of-the-art facilities and a skilled team proficient in analytical testing and regulatory affairs underline its commitment to operational excellence. Avid Bioservices continuously adapts its service offerings to address the evolving challenges in biologics manufacturing, ensuring high-quality and efficient treatment production.
Competitive Landscape
Avid competes in a dynamic and challenging marketplace alongside other renowned CDMOs. What sets it apart is its specialized focus on biologics, its comprehensive suite of services, and its dedication to maintaining robust regulatory standards. These factors enable the company to offer customized solutions that are not only technically advanced but also meticulously aligned with industry best practices.
Customer Focus and Value Proposition
The core value proposition of Avid Bioservices lies in its ability to support the sustainable innovation of biopharmaceutical products. By integrating advanced process development with scalable manufacturing solutions, the company helps clients bring complex biologics to market efficiently. Its customer-centric approach, underscored by tailored solutions and a deep understanding of regulatory frameworks, enhances overall client value across the product lifecycle.
Conclusion
With a rich history in biologics production, Avid Bioservices stands out for its unwavering commitment to quality, comprehensive service offerings, and precise, regulatory-compliant manufacturing practices. The company remains a crucial partner for biotechnology and pharmaceutical innovators looking for dependable, full lifecycle development and manufacturing solutions, underpinned by a deep well of industry expertise and operational excellence.
Avid Bioservices (NASDAQ:CDMO) announced the completion of expansions at its mammalian cell manufacturing facilities in Tustin, California. The newly expanded CGMP suites are expected to generate an additional $100 million in annual revenue, while process development capacity has doubled, potentially adding another $25 million. The first customer project in the expanded capacity will commence this month. The enhancements reflect a growing demand for Avid's services, with the company noting a record backlog. Avid aims to maximize its total revenue-generating capacity to approximately $400 million with ongoing projects, including a new cell and gene therapy facility.
Avid Bioservices (NASDAQ:CDMO) reported third quarter revenue of $38.0 million, a 21% increase year-over-year. The company signed $67 million in new business orders, resulting in a backlog of $176 million, up 26% from the previous year. The mammalian cell manufacturing facility is now operational, with expansions expected to add approximately $120 million in revenue capacity by the end of Q1 2023. Avid reaffirms its FY 2023 revenue guidance of $145-$150 million. However, gross margin decreased to 26% for the quarter, compared to 29% last year. The company recorded a net income of $0.5 million ($0.01 per share), down from $2.2 million ($0.04 per share) in Q3 2022.
Avid Bioservices, Inc. (NASDAQ:CDMO) announced it will release its third-quarter fiscal year 2023 financial results on March 13, 2023, after market close. A webcast will be held at 1:30 PM PT (4:30 PM ET) where senior management will discuss the financial outcomes and recent corporate updates. As a dedicated biologics contract development and manufacturing organization, Avid provides comprehensive services to biotechnology and pharmaceutical companies, leveraging over 30 years of experience in manufacturing monoclonal antibodies and recombinant proteins.
Avid Bioservices reported a second quarter revenue of $34.8 million, a 33% increase year-over-year. The company signed $26 million in new business orders, boosting the backlog to $147 million, a 23% rise year-over-year. Revenue guidance for fiscal 2023 has been adjusted to between $145 million and $150 million. However, gross margin fell to 12% from 35% a year earlier, attributed to increased operational costs. Avid continues expansions in cell and gene therapy facilities, with expectations to complete significant phases by mid-2023.
Avid Bioservices, Inc. (NASDAQ:CDMO) will announce its second quarter fiscal year 2023 financial results on December 6, 2022, after market close. A conference call is scheduled for 1:30 PM Pacific Time (4:30 PM Eastern Time) the same day, where senior management will discuss these results and highlight recent corporate developments. Avid specializes in contract development and manufacturing services for the biotechnology and biopharmaceutical sectors, with nearly 30 years of experience in producing biologics.
Avid Bioservices, Inc. (NASDAQ:CDMO) has appointed Oksana Lukash as vice president of people, bringing over 20 years of HR expertise in the life sciences sector. Previously at Oncocyte Corporation, she led major acquisitions and expanded the workforce significantly with low turnover rates. CEO Nick Green expressed confidence in her ability to enhance Avid’s workplace culture and optimize team performance. Avid specializes in contract development and manufacturing for biologics, offering a full range of services including process development and CGMP manufacturing.
Avid Bioservices (NASDAQ:CDMO), a biologics contract development and manufacturing organization, will participate in the Credit Suisse 31st Annual Healthcare Conference from November 7-10, 2022. Nick Green, the president and CEO, is scheduled to deliver a presentation on November 9, 2022, from 12:50 to 1:20 p.m. Pacific Time at the Terranea Resort in Rancho Palos Verdes, CA. The company focuses on providing high-quality development and manufacturing services to the biotech and pharmaceutical sectors, boasting nearly 30 years of experience in producing monoclonal antibodies and recombinant proteins.
Avid Bioservices (NASDAQ:CDMO), a biologics contract development and manufacturing organization, will participate in the RBC Global CDMO Conference on October 3-4, 2022. CEO Nick Green will be featured in a fireside chat scheduled for October 3 from 12:15 to 12:45 p.m. Eastern Time. The conference will be hosted virtually, and a webcast of the conversation will be available online. Avid specializes in CGMP manufacturing of biologics and offers a range of services, including process development and regulatory submissions support.
FAQ
What core services does Avid Bioservices provide?
How does Avid Bioservices serve the biotech and pharmaceutical industries?
What distinguishes Avid Bioservices in the competitive CDMO market?
How does Avid ensure quality and compliance in its manufacturing processes?
What is the significance of process development in Avid Bioservices' operations?
How does Avid Bioservices support its clients throughout the product lifecycle?
Who are the typical customers of Avid Bioservices?
How does Avid Bioservices maintain its industry expertise?
